Enasidenib for Relapsed/Refractory Acute Myeloid Leukemia With IDH2 Mutations: Optimizing the Patient Experience

  H&O  What is the mechanism of action of enasidenib? GR Enasidenib (Idhifa, Celgene/Agios) is an oral, small molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) […]